Diaryl ether pyridone compound as well as preparation method and application thereof

The invention belongs to the field of medicinal chemistry, and particularly relates to a diaryl ether pyridone compound as well as a preparation method and application thereof. The invention relates to a compound containing a general formula I and pharmaceutically acceptable salts, isomers, metaboli...

Full description

Saved in:
Bibliographic Details
Main Authors JIANG WENHUA, LI WENQIANG, WU XIAOXING, WANG XIAOHUI, HOU QIANGQIANG, YANG KEXIN
Format Patent
LanguageChinese
English
Published 25.04.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention belongs to the field of medicinal chemistry, and particularly relates to a diaryl ether pyridone compound as well as a preparation method and application thereof. The invention relates to a compound containing a general formula I and pharmaceutically acceptable salts, isomers, metabolites, prodrugs, solvates or hydrates thereof. The BET small-molecule inhibitor with a selective inhibition effect on BD2 is novel in structure and good in BD2 selectivity, and the selectivity of the BET small-molecule inhibitor is far higher than that of a clinical compound ABBV-744. In the aspect of cell activity, the compound is equivalent to ABBV-744. 本发明属于药物化学领域，具体涉及一种双芳基醚吡啶酮类化合物及其制备方法与应用。含有通式I的化合物及其药学上可接受的盐、异构体、代谢产物、前药、溶剂合物或水合物。本发明提供一类对BD2具有选择性抑制作用的BET小分子抑制剂，结构新颖，BD2选择性好，且选择性远高于临床化合物ABBV-744。在细胞活性方面，该类化合物与ABBV-744相当。
Bibliography:Application Number: CN202310026957